MycoMedica Life Sciences is focused on developing and delivering fungi-based therapeutic drugs centered on the Stamets Stack. The Stamets Stack is a novel combination of ingredients not found together in nature designed to unlock the potential effectiveness of psilocybin for psychiatric and neurological disorders. The company’s initial research is centered on microdosing, which the company says can improve affordability and accessibility for patients. Leadership includes Paul Stamets as CEO and Founder and Sanjay Dubé M.D. as President and Chief Medical Officer. MycoMedica raised $60 million in financing to advance its next stage of operations. The company intends to use the proceeds to pursue pre-clinical research and initial clinical trials on the path to an FDA Investigational New Drug (IND) application.

Total raised

$60M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2022